<DOC>
	<DOCNO>NCT01363661</DOCNO>
	<brief_summary>Molsidomine use add-on treatment standard care therapy superior placebo use also add-on treatment standard care therapy improve endothelial function ( endothelium score measure reactive hyperemia - peripheral arterial tonometry [ RH-PAT ] ) 12 month treatment patient stable angina patient undergo elective percutaneous coronary intervention . The study double-blind , parallel-group , randomise , multicentre , sequential , placebo-controlled study . The device use determine RH-PAT EndoPAT . Duration treatment = one year .</brief_summary>
	<brief_title>Effect Molsidomine Endothelial ( Internal Layer Blood Vessels ) Dysfunction Patients With Angina Pectoris</brief_title>
	<detailed_description>A Data Steering Committee ( DSC ) blindly assess recruitment rate , variability RH-PAT within centre , safety regular basis . Sequential approach : - In first phase ( Phase A ) study , 180 patient enrol order get least 50 completers 12 month treatment . A statistical evaluation primary endpoint do Independent Biostatistician approximately 50 patient complete study accordance protocol . - The result examine Independent Data Monitoring Committee ( IDMC ) ass result advise sponsor : 1 . Continue study primary objective achieve difference two group least 10 % ( difference consider clinically significant ) . In case , sample size recalculate Independent Biostatistician take account actual difference variability . The total number patient enrolled addition Phase B calculate precision . Depending IDMC recommendation , number investigating centre increase Phase B . If right number patient already enrol , Phase B start . The study stop enrol patient complete one-year treatment period . 2 . Terminate study , difference two group less 10 % . 3 . Consider study complete primary endpoint achieve . Treatment allocation : Balanced allocation molsidomine placebo ( 1:1 ) stratification consumption statin , type stent ( drug-eluting stent bare-metal ) consumption angiotensin-converting enzyme inhibitor ( ACEIs ) . Data collection : Electronic Case Report Form ( eCRF ) . Duration study : A minimum 30 month ( 16 month inclusion 14 month study ) Phase A . Number investigational centre : - Up 10 centre Phase A - To determine Phase B base Phase A .</detailed_description>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina , Stable</mesh_term>
	<mesh_term>Molsidomine</mesh_term>
	<criteria>Aged least 18 year . No treatment molsidomine and/or longacting nitrate ( oral patch ) 48 hour month precede percutaneous coronary intervention ( PCI ) treatment drug within 3 day PCI . Patients investigator believe and/or Legally Acceptable Representative ( LAR ) comply requirement protocol . Written informed consent patient LAR . Patients underwent PCI stable angina pectoris one month prior start study . Patients present endothelial dysfunction Month 0 ( score EndoPAT &lt; 0.40 ) . Premenopausal woman . Patient clinicallyactive malignancy . Known major renal insufficiency know significant hepatic insufficiency . History psychological disorder , mental dysfunction , alcohol drug abuse factor might interfere ability cooperate study . Participation another clinical trial yet reach primary endpoint primary endpoint previous month . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( vaccine , drug device ) . Hypersensitivity molsidomine one excipients . Periprocedural infarction : creatine kinasemuscle/brain ( CKMB ) &gt; 3 time upper reference limit . Clinically significant abnormal prePCI CKMB troponin : elevation upper reference limit . Intolerance galactose , deficiency Lapp lactase glucosegalactose malabsorption . Left ventricular insufficiency ( New York Heart Association [ NYHA ] class III IV ) ejection fraction &lt; 35 % . Acute circulatory insufficiency ( e.g . cardiogenic shock ) . Hypotension : systolic blood pressure &lt; 100 mmHg and/or diastolic blood pressure &lt; 70 mmHg . Atrial fibrillation Acute myocardial infarction precede month . Unsuccessful PCI : residual stenosis least 50 % . Patient take phosphodiesterase5 inhibitor , sildenafil ( Viagra® ) , vardenafil ( Levitra® ) tadalafil ( Cialis® ) Patient take nebivolol ( Nobiten® ) Patient take ibuprofen + Larginine excipient ( Spidifen® ) Patient meeting contraindication ( ) Coruno® . Please refer Coruno® ( molsidomine 16 mg o.d . ) Summary Product Characteristics ( SPC ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>angina pectoris</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>